ALK Positive Lung Cancer UK shared a post on LinkedIn:
“Today, the Scottish Medicines Consortium officially announces the approval of Alectinib (Alecensa) for post-surgical treatment of ALK-positive lung cancer in stages IB to IIIA, aimed at preventing the recurrence of cancer.
This approval offers a new treatment option for patients in Scotland within this specific group, significantly improving disease-free survival compared to traditional chemotherapy.
Alectinib is already approved for similar use in England.
Patients now have access to an effective treatment that can notably extend the disease-free period following surgery, improving their quality of life.”
More posts featuring ALK Positive Lung Cancer UK.